CPN2

Across TCGA pan-cancer cohorts, CPN2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CPN2 data layer compared with 21 for mass-spec protein and 9 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher CPN2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPN2 expression acts as an unfavorable survival marker.

LGG, SARC, and GBM are the cancer types where CPN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.236	0.738	.018	9	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
GBM	OS	Median	All	0.080	0.419	<.001	6	view →
ESCA	DFS	Median	II,III,IV	0.242	0.527	.036	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BRCA	OS	Median	All	0.226	0.580	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CPN2–LGG (DFS)

Open the LGG breakdown →